Crizotinib in ROS1-rearranged non-small-cell lung cancer.
New England Journal of Medicine.
Times cited: 907
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
Clinical Cancer Research.
Times cited: 174